Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

40.81 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
News headline image
Thin Trading and High Hopes: Markets Eye a 'Santa Claus Rally' as 2025 Draws to a Close
As the sun sets on a volatile but ultimately record-breaking year, Wall Street has entered its final, holiday-shortened trading week of 2025. With the S&P 500 sitting at a historic peak of 6,904 as of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Santa Claus Rally Solidifies as S&P 500 Secures Third Consecutive Winning Session Amid Economic Resilience
The U.S. equity markets continued their year-end ascent on Tuesday, December 23, 2025, as the S&P 500 (INDEXSP:.INX) notched its third consecutive winning session. This momentum, often referred to as... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗
Via Stocktwits
News headline image
These stocks are gapping in today's session ↗
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
Nasdaq, S&P 500 Futures Tread Caution Ahead Of GDP, Confidence Data: Why NVO, ZIM, SIDU Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Loss ↗
The Danish drugmaker expects to launch the pill in the U.S. in January. 
Via Stocktwits
News headline image
The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. 
Via The Motley Fool
News headline image
Novo Nordisk (NYSE:NVO) Identified as a 'Decent Value' Stock with Strong Fundamentals ↗
Novo Nordisk (NVO) presents a value opportunity, trading at a discount to peers with top-tier profitability and solid financial health. 
Via Chartmill
News headline image
2026 Market Outlook: Key Themes and Predictions
As the final weeks of 2025 draw to a close, the global financial landscape is entering a pivotal transformation. The "AI Gold Rush" that defined the previous two years is evolving from a speculative... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Prediction: 1 Healthcare Giant Set to Soar in 2026 ↗
Novo Nordisk has struggled this past year, but its beaten-down valuation has made it a bargain buy today. 
Via The Motley Fool
Topics ETFs
News headline image
The Weight of a Trillion: Inside Eli Lilly’s Pharmaceutical Hegemony
On this day in late 2025, Eli Lilly and Company (NYSE: LLY) stands as the undisputed titan of the global pharmaceutical industry. Having crossed the historic $1 trillion market capitalization threshold... 
Via PredictStreet
Topics Economy World Trade
News headline image
Better Buy in 2026: Novo Nordisk or Intuitive Surgical? ↗
These struggling healthcare stocks haven't said their last words. 
Via The Motley Fool
News headline image
Better Pharmaceutical Buy: Eli Lilly vs. Novo Nordisk ↗
These two healthcare stocks have strong growth prospects, but they've been going in opposite directions. 
Via The Motley Fool
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
New York, NY – December 16, 2025 – Pfizer Inc. (NYSE: PFE) today delivered a sobering financial outlook for 2026, projecting revenue and adjusted earnings per share (EPS) that fell short of Wall... 
Via MarketMinute
Topics Intellectual Property
News headline image
From Insulin Injections to Functional Cures: Regenerative Medicine Reshapes Diabetes
Issued on behalf of Avant Technologies Inc. 
From USA News Group
Via GlobeNewswire
News headline image
Profit Powerhouse: Strong Earnings Outlook Defies Market Slips, Signaling Continued Bull Run for US Stocks
Despite recent pockets of volatility and "slips" in the U.S. stock market during late 2025, a robust corporate profit outlook is emerging as a powerful counter-narrative, fueling investor optimism and... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Pfizer Adds to Its Big Bet on Weight Loss Drugs ↗
Via MarketBeat
News headline image
Eli Lilly Just Delivered Fantastic News to Investors ↗
Eli Lilly shares have climbed in the double digits this year. 
Via The Motley Fool
News headline image
2 Predictions for Novo Nordisk in 2026 ↗
The company's worst days might be behind it. 
Via The Motley Fool
News headline image
My Top 10 Stocks to Buy for 2026 ↗
These players are well-positioned to potentially gain next year -- and over time. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Novo Nordisk Stock Topped the Market on Thursday ↗
A proposed new federal law could provide some competitive guardrails for the company's most important product. 
Via The Motley Fool
News headline image
Navigating Nuance: Tech Innovation, Healthcare Revival, and Energy's Evolving Landscape Shape Late 2025 Markets
As December 2025 unfolds, global financial markets are characterized by a delicate balance of cautious optimism and persistent uncertainty. A "Santa Claus rally" sentiment prevails, fueled by... 
Via MarketMinute
Topics Artificial Intelligence Economy Electric Vehicles
News headline image
Novo Nordisk (NVO) Q3 2025 Earnings Transcript ↗
Novo Nordisk (NVO) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Eli Lilly's Retatrutide Soars: Unprecedented Trial Results Propel Pharma Giant, Ignite Obesity Market
Eli Lilly and Company (NYSE: LLY) has once again sent ripples through the pharmaceutical world with the announcement of groundbreaking Phase 3 trial results for its investigational obesity drug,... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Golden Cross Alert: 3 Stocks With Major Upside Potential ↗
Via MarketBeat
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Following a significant price increase due to the company's industry-leading weight loss drugs, investors must now consider what comes next. 
Via The Motley Fool
Topics Intellectual Property
News headline image
3 Absurdly Cheap Stocks That Look Like Steals Right Now ↗
These stocks are down more than 20% this year, but they possess lots of upside potential over the long term. 
Via The Motley Fool
Topics Economy World Trade
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.